Latest Content

First Patient Dosed in Trial for Chemotherapy-Induced Neuropathic Pain

March 18th 2025, 3:32pm

By Ryan Scott

Article

The first patient has been dosed in a phase 2b trial evaluating the first-in-class agent Halneuron for those with neuropathic pain following chemotherapy.

The Role of Circulating Tumor DNA in Breast Cancer Monitoring

March 18th 2025, 1:00pm

By Dr. Debu Tripathy

Video

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.

Elahere Shows Consistent Survival Benefit in Ovarian Cancer Subset

March 17th 2025, 9:00pm

By Spencer Feldman

Article

Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial.

Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia

March 17th 2025, 7:00pm

By Ryan Scott

Article

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.

A Picture is Worth Ten Thousand Words When it Comes to Cancer

March 17th 2025, 5:00pm

By Felicia Mitchell

Article

Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.

Precision Radiation Therapy Makes Strides in Colorectal Cancer Care

March 17th 2025, 4:00pm

By Dr. Yufei Liu

Video

Dr. Yufei Liu discusses how updates to precision radiation therapy are reshaping colorectal cancer care.

FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer

March 17th 2025, 3:00pm

By Spencer Feldman

Article

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel treatment for the disease.

SBRT May Offer Best Control Rates for Larger RCC Tumors, Study Finds

March 17th 2025, 1:00pm

By Ryan Scott

Article

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options.

Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset

March 16th 2025, 6:00pm

By Spencer Feldman

Article

Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.

Why It’s Important to Have Hard Conversations in Breast Cancer Care

March 16th 2025, 2:00pm

By Alex Biese

Article

CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.

Ongoing Trials Aim to Advance HER2-Negative Breast Cancer Treatment

March 15th 2025, 6:00pm

By Ryan Scott

Article

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.

Jelmyto Maintains Effectiveness Over Time in Bladder Cancer Subtype

March 15th 2025, 2:00pm

By Spencer Feldman

Article

Jelmyto demonstrated long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months.

PSMA-PET Improves Detection of Metastases in High-Risk Prostate Cancer

March 14th 2025, 9:00pm

By Ryan Scott

Article

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by conventional imaging.

Myeloma Awareness Month and Acknowledging Early Symptoms of The Disease

March 14th 2025, 7:00pm

By Dr. Joseph Mikhael

Video

Dr. Joseph Mikhael discusses the overlooked symptoms of multiple myeloma in honor of Myeloma Awareness Month.

Triple-Positive Breast Cancer Research Saved My Daughter’s Life

March 14th 2025, 5:00pm

By Debbie Legault

Article

Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved from cancer.